Diabetes isn't only about drugs. There's also "hardware" that works alongside them — a tiny sensor under the skin that reads your blood sugar every few minutes, and an insulin pump that doses the drug automatically. Once those two can talk to each other, they become an "artificial pancreas" that adjusts your insulin all day and all night. This is a business growing from ~$12B toward $50B — with one big question hanging over it: will GLP-1 weight-loss drugs kill this market, or make it bigger?
Beta Bionics Wins FDA Clearance for Mint Patch Pump, Trims 2026 Revenue Outlook
Beta Bionics secured FDA clearance for its Mint patch pump, marking the company's entry into the tubeless patch pump market alongside its existing iLet automated insulin delivery platform. The company also unveiled its next-generation 3D Intelligence insulin dosing algorithm, which has been submitted to the FDA through the 510(k) pathway and is currently under review. Beta Bionics lowered its full-year 2026 revenue guidance to $121-$126 million from the previous $131-$136 million, citing the possibility that prospective iLet customers may delay purchases ahead of Mint's launch, while gross margin guidance for 2026 remains unchanged at 58.5%-59.5%. The company expects to begin full U.S. commercialization of Mint in the first quarter of 2027, earlier than previously targeted, with manufacturing capacity of at least 1.5 million disposable units during the year, and expects to commercialize iLet 3D by the end of 2026 with Mint 3D launching alongside the full U.S. rollout of Mint. Mint is likely to launch exclusively through the pharmacy channel, where roughly 40% of insured U.S. lives are expected to have initial access, with coverage anticipated to expand to at least 50% within the first year. Shares of BBNX surged more than 15% following the announcement; the stock has lost 27.2% year to date, and the company currently has a market capitalization of $865.2 million.
Medtronic Raises Fiscal 2027 Outlook on Strong Heart Device Demand
Medtronic raised the lower end of its fiscal 2027 profit forecast and lifted its revenue growth outlook, citing strong demand for heart devices used in complex cardiovascular procedures. The Ireland-based company raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90 while keeping the upper end at $6.00, against an analyst average of $5.95, and now expects annual organic revenue growth of 7.25% to 7.75%, up from 6.75% to 7.25% previously. First-quarter fiscal 2027 revenue reached $9.756 billion, up 13.7% both reported and organically, beating the $9.55 billion analyst consensus, with adjusted earnings per share of $1.45 topping the $1.39 estimate. Growth was broad-based across segments, with Cardiovascular revenue up 19.5%, Diabetes up 16.9%, Neuroscience up 10.3%, and Medical Surgical up 10.0%, though Medtronic said about $570 million of the quarter's growth came from an extra week in the reporting period. The guidance still includes the diabetes business, which Medtronic has said it may fully separate before fiscal year-end, though CFO Thierry Pieton said the company is not under pressure to rush that timeline.
Beta Bionics Fair Value Estimate Rises to US$21.67 as Analysts Reassess Pipeline Timing
Beta Bionics' estimated fair value has been lifted to about US$21.67 from roughly US$19.80, a revision tied to Wall Street research reassessing the company's pipeline, its expected patch pump entry and the timing of its Type 2 diabetes and fully closed loop indications. Several firms, including Truist, UBS, Leerink and Goldman Sachs, have raised their price targets on the stock, with Truist and UBS pointing to FDA clearance of the Mint patch pump and updated launch timing as key execution milestones as Mint enters the patch pump segment as an alternative to Omnipod. UBS and BofA cited clearer timelines for the Type 2 diabetes and fully closed loop indications, while Truist pointed to survey work suggesting Beta Bionics is gaining share, with iLet screening well for pump naive patients entering the market. Not all research moved in the same direction: Baird and BofA kept Neutral ratings despite higher targets, William Blair initiated at Market Perform and flagged the stock's premium valuation versus Tandem Diabetes, and Ladenburg trimmed its target to US$30.40 from US$32. Behind the fair value change, the model's revenue growth input shifted to about 37.32% from about 35.78%, the net profit margin assumption moved to about 12.58% from about 11.76%, the future P/E assumption adjusted to about 33.33x from about 36.27x, and the discount rate rose to about 7.48% from about 7.38%.
Beta Bionics Plans $125M Public Offering, Shares Fall 8%
Beta Bionics announced plans for an underwritten public offering of $125M of common stock. The company also intends to grant underwriters a 30-day option to purchase up to an additional $18.75M of common stock. Beta Bionics expects to use the net proceeds for general corporate purposes, including commercialization of Mint, manufacturing expansion, research and development, clinical development and working capital. Funds may also support product enhancements and potential strategic opportunities, alongside operating expenses. BBNX shares fell 8% in post-market trading.
Medtronic plc reported fiscal first-quarter 2027 revenue of nearly $9.8 billion, up 13.7% organically, while non-GAAP diluted EPS rose 15.1% to $1.45. The company raised its full-year organic revenue-growth forecast to 7.25%-7.75% from 6.75%-7.25% and lifted the lower end of its non-GAAP diluted EPS guidance to $5.94 from $5.90. Cardiovascular revenue increased 18.9% organically to $3.927 billion, with Cardiac Ablation Solutions up 88%, while Neuroscience grew 9.3% and Medical Surgical increased 10.2%. The quarter included an extra fiscal week that Medtronic estimates benefited organic growth by approximately $570 million, and non-GAAP operating margin rose only 10 basis points to 23.7%. Medtronic also committed $700 million to Cornerstone Robotics for distribution rights to its Sentire surgical system in select markets outside the United States and agreed to invest up to $80 million in Pi-Cardia, with an option to acquire the company for up to $210 million, as it proceeds with the separation of its diabetes division by the end of the year.
Abbott wins FDA approval for dual-energy TactiFlex Duo ablation catheter
Abbott has received U.S. Food and Drug Administration approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy device that combines pulsed field ablation and radiofrequency energy in a single catheter to treat complex cases of atrial fibrillation. The approval, announced September 8, 2026, is based on results from the FlexPulse IDE study, which showed favorable safety and effectiveness in patients with paroxysmal AFib. Abbott will begin commercial cases across the country in the coming weeks. This marks the company's fifth major electrophysiology approval in just over a year, following European approvals of the Amulet 360 and TactiFlex Duo, and U.S. and European approvals of the Volt PFA System in 2025. The catheter integrates with Abbott's EnSite X EP System, which provides real-time feedback and a PFA Index to guide lesion formation.
Sinocare Secures Multiple Medical Device Registration Certificates
Sinocare announced that the company recently obtained multiple medical device registration certificates from the National Medical Products Administration and the Hunan Provincial Medical Products Administration. These include a Class III continuous glucose monitoring system, with the applicable population expanded to diabetes patients aged 2 and above, a wear time of up to 15 days, and no calibration required. In addition, Class II certificates for blood glucose meters, blood glucose test strips, and glycated hemoglobin assay kits were renewed. These products cover both medical institutions and home settings, and will further strengthen the company's diabetes management product line.
Mobile ECG Devices Market to Reach $9.03 Billion by 2035
A new report from ResearchAndMarkets.com forecasts that the global mobile ECG devices market will grow to $9.03 billion by 2035, up from approximately $3.16 billion in 2025. The market expanded at a compound annual growth rate of 12.6% from 2020 to 2025, and is projected to increase to $5.5 billion by 2030, representing a CAGR of 11.7% between 2025 and 2030, with growth continuing at a CAGR of 10.4% from 2030 to 2035. The report highlights that monitoring ECG systems accounted for 58.4% of the market in 2025, or about $1.85 billion, while diagnostic ECG systems are expected to be the fastest-growing type segment through 2030. By modality, handheld devices led with a 48.9% share, but the band segment is projected to grow fastest at a CAGR of 15.7%. North America was the largest regional market in 2025, with 33.4% of global revenue, while Asia-Pacific and the Middle East are forecast to be the fastest-growing regions through 2030. Key trends include AI-enabled wearable ECG bands, remote monitoring, and point-of-care diagnostics, driven by telemedicine and preventive care.
Medtronic reported first-quarter fiscal 2027 adjusted earnings per share of $1.45, up 15.1% year over year and beating the Zacks Consensus Estimate by 4.32%, while revenues rose 13.7% to $9.76 billion, surpassing expectations by 3.02%. The company raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from 6.75%-7.25% and lifted adjusted EPS guidance to $5.94-$6.00 from $5.90-$6.00. Cardiovascular led segment growth with a 19.5% reported increase, while Neuroscience, Medical Surgical, and Diabetes also posted strong organic gains. Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics, and announced a strategic partnership with Cornerstone Robotics and an investment in Pi-Cardia. Shares rose nearly 5% in pre-market trading following the announcement.
Medtronic raises fiscal 2027 guidance after strong first quarter
Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and raised its full-year guidance. The company's non-GAAP diluted EPS of $1.45 beat expectations, while GAAP EPS was $1.14. Medtronic now expects fiscal 2027 organic revenue growth of 7.25% to 7.75%, up from prior guidance of 6.75% to 7.25%, and non-GAAP EPS of $5.94 to $6.00. Growth was broad-based, with the Cardiovascular portfolio up 18.9% organically, Neuroscience up 9.3%, Medical Surgical up 10.2%, and Diabetes up 14.9%. The company also announced strategic investments and partnerships, including an investment in Pi-Cardia and a partnership with Cornerstone Robotics, and completed acquisitions of Scientia Vascular and SPR Therapeutics.
FDA Approves Abbott's First Wearable Dual Ketone and Glucose Monitor
The U.S. Food and Drug Administration on Tuesday approved Abbott Laboratories' Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older, making it the first wearable in the U.S. to continuously monitor ketone levels and the first global system to track blood sugar and ketones simultaneously in a single unit. The agency granted marketing authorization via the De Novo pathway for new low-to-moderate-risk devices, following a review of six clinical studies involving over 600 participants that demonstrated accurate tracking of clinically significant ketone variations. The sensor, which offers up to 10 days of wear, alerts users when ketones rise, replacing single-point urine or blood tests. Abbott is working with pump companies to integrate the sensor with automated insulin delivery systems, expecting compatibility with iLet from Beta Bionics Inc and twiist from Sequel Med Tech by the end of this year, and with systems from Insulet Corp and Tandem Diabetes Care Inc by 2027, alongside an exclusive integration with MiniMedGroup Inc for smart dosing systems. William Blair analyst Brandon Vazquez noted the clearance may create a new competitive dynamic for DexCom Inc shares, with the sensor likely most competitive in the pediatric population once integrated with AID pumps next year.
Abbott's Amulet 360 Receives CE Mark for Stroke Prevention in AFib Patients
Abbott announced it has received CE Mark for its next-generation Amulet 360 Left Atrial Appendage Occluder, designed to reduce stroke risk in patients with non-valvular atrial fibrillation. The device, which seals the left atrial appendage to prevent blood clots, builds on Abbott's first-generation LAA occluder with a softer, more conformable lobe and smaller anchors to treat a wider range of anatomies. Clinical data from the VERITAS Study, involving 400 patients at over 30 hospitals, showed successful implantation in 99.8% of patients, no early complications, and complete closure in 93.9% of patients at 45 days. The first European procedures were completed in Germany and Denmark, with broader rollout planned in coming weeks. This approval marks Abbott's fourth major electrophysiology approval in just over a year, following the Volt PFA System and TactiFlex Duo.
Huayang Intelligent 2026 Interim Report: Drug Delivery Devices Surge, Earnings Steady and Cash Flow Improves
Huayang Intelligent released its 2026 interim report on August 26. Driven by its dual engines of micro motors and precision drug delivery devices, the company achieved steady earnings growth during the reporting period, with a significant improvement in operating cash flow. Financial data show that the company recorded operating revenue of 251 million yuan, up 6.74 percent year on year; net profit attributable to the parent company of 18 million yuan, up 3.74 percent; non-GAAP net profit of 16 million yuan, up 14.62 percent; and net cash flow from operating activities of 50 million yuan, a sharp year-on-year increase of 221.10 percent, turning from a net outflow to a net inflow. In terms of business structure, revenue from micro motors and components fell 1.91 percent year on year to 214 million yuan, accounting for about 85 percent of total revenue; revenue from the precision drug delivery device business surged 126.29 percent year on year to 34 million yuan, becoming a second growth curve. The company seized opportunities from the expanding market for GLP-1 drugs and growth hormone, with rapid order fulfillment for injection pens and other products, offsetting pressure from the decline in its traditional business. Looking ahead, precision drug delivery devices are expected to maintain strong momentum, but attention should be paid to risks such as raw material price fluctuations, weaker-than-expected recovery in home appliance demand, and longer approval cycles for medical devices.
Atrial Fibrillation Device Market to Reach $29B by 2035
The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.
MiniMed Flex System Ships in U.S. with Abbott Instinct Sensor
MiniMed Group announced on August 17 that its MiniMed Flex automated insulin delivery system is now commercially shipping in the U.S., integrated with Abbott Laboratories' Instinct continuous glucose sensor. The system pairs MiniMed's smallest, only app-controlled insulin pump with Abbott's world's-smallest 15-day sensor, holds 300 units of insulin, and connects to a 7-day Extended infusion set. Real-world data shows the system reaches 80% Time in Range and over 90% overnight. Abbott reported $12.6 billion in quarterly revenue for Q2 2026, a 13.0% reported growth rate, and raised full-year EPS guidance to $5.45–$5.60. MiniMed, with a market cap of roughly $5.67 billion, is scheduled to report fiscal Q1 2027 results on September 1, 2026.
Abbott's Medical Devices Arm Drives Growth Through Electrophysiology and Diabetes Care
Abbott Laboratories' Medical Devices business continues to be one of the company's strongest growth engines, supported by accelerating momentum in electrophysiology, continued adoption of cardiovascular technologies and the large long-term opportunity in continuous glucose monitoring. The company launched the next-generation Volt PFA catheter in the United States in May and expects to move from a limited release to a full commercial launch in the coming quarters. Abbott estimates that roughly 75-80 million people globally could realistically use CGM technology compared with only about 15 million users today, giving the company considerable runway. Abbott received CE Mark for Libre Duo in the second quarter and plans to begin its international rollout in fall 2026. The cardiovascular pipeline acts as an additional growth catalyst, with clinical programs for a balloon-expandable TAVR valve, a leadless conduction-system pacing device based on AVEIR, a Cephea mitral replacement valve and a peripheral IVL device supporting growth into 2029 and beyond.
Abbott and Alphabet Partner to Integrate Lingo Glucose Data with Google Health AI
Abbott Laboratories and Alphabet announced a multi-year partnership on August 11 to embed data from Abbott's non-prescription Lingo biowearable directly into the Google Health app, combining real-time metabolic insights with Google's AI Health Coach for personalized nutrition, sleep, and recovery recommendations. Abbott reported second-quarter 2026 sales of $12.59 billion, up 13.0% reported, with adjusted diluted EPS of $1.31 and raised full-year EPS guidance to $5.45–$5.60, while Alphabet's revenue spiked 24% year-over-year to $119.8 billion and Google Cloud revenue surged 82% on Gemini model adoption. Hedge fund interest diverged, with 73 funds holding Abbott shares in Q1 2026, up from 71, while Alphabet holdings dipped to 201 funds from 203. Investors will watch whether the Lingo-Google Health integration drives user retention for Abbott and whether Google can translate consumer health engagement into enterprise healthcare wins.
Tenon Medical outlines sacropelvic launches after FDA clearance
Tenon Medical reported second quarter revenue of $1.3 million, up 127% year over year, and gross profit of $0.8 million, up 232%, while outlining a cadence of sacropelvic product launches over the next six to nine months. The company received FDA 510(k) clearance for its Catamaran SI Joint Fusion System on July 2, with updated instruments expected to improve margins beginning in Q3. Tenon also closed a public offering on July 1 for gross proceeds of $4.2 million, adding to its $1.7 million cash position at quarter end. Management did not provide formal guidance but said an enhanced SImmetry+ system will become clinically active in Q3 and a novel posterior technology is being prepared for FDA submission.
Abbott Laboratories and Google Health Partner on AI Glucose Tracking
Abbott Laboratories and Google Health announced a multi-year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI-driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real-world metabolic health studies using anonymized Lingo data combined with Google's AI capabilities. The agreement is positioned to support Abbott's role in personalized wellness and wearables by linking its sensor technology with widely used digital health platforms.
Biotech Stocks Hit 52-Week Highs on Earnings and Pipeline Updates
Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.
Autoinjectors Market to Reach USD 300.46 Billion by 2031, Growing at 18.7% CAGR
The global autoinjectors market is projected to grow from USD 127.30 billion in 2026 to USD 300.46 billion by 2031, at a compound annual growth rate of 18.7%, according to a new report from MarketsandMarkets. Growth is driven by the rising prevalence of chronic and autoimmune diseases, increasing regulatory approvals for autoinjector-based therapies, and greater adoption of self-administered medicines. The Asia Pacific region is expected to register the highest growth rate, while the finished formulation autoinjectors segment held the largest market share in 2025. Leading companies include Novo Nordisk, Eli Lilly and Company, AbbVie, Amgen, Sanofi, AstraZeneca, Becton, Dickinson and Company, Ypsomed AG, SHL Medical, Owen Mumford, Phillips-Medisize, Halozyme, GSK, and Johnson & Johnson.
Becton Dickinson shares rise 6.8% after Q3 beat and GLP-1 delivery partnerships
Becton, Dickinson and Company shares climbed 6.8% after reporting third-quarter fiscal 2026 results that beat expectations and announcing new GLP-1 delivery partnerships. Sales rose to US$4,983 million while net income fell to US$377 million, and the company modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. BD highlighted strong momentum in biologic drug delivery and a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen platform in chronic disease treatment. The affirmed US$4.20 annual dividend and share price recovery suggest the market views the quarter as a mild positive, though the sharp drop in year-to-date net income and a large recent one-off loss keep the quality of earnings in focus.
MannKind Reports Record Revenue and Major Catalysts in Q2 2026 Earnings Call
MannKind Corp reported second-quarter revenue of $109.4 million, up 43% year-over-year, driven by strong growth in marketed products and royalties. The company achieved all three major 2026 catalysts: Afrezza pediatric approval, Furo6 ReadyFlow approval, and positive Phase 1b data for nintedanib DPI in IPF patients. Afrezza pediatric launch shows early momentum with all 20 priority accounts writing prescriptions, while Furo6 revenue grew 43% quarter-over-quarter on a 49% increase in units sold. MannKind posted a GAAP net loss of $19 million compared to net income of $700,000 in the prior year quarter, and expects a $45 million CVR payment in Q3. The company raised $50 million in a pipe financing, ending the quarter with pro forma cash of $161 million.
Intuitive Surgical Shares Fall 37% to $355, Bernstein Targets $685
Intuitive Surgical shares have fallen 37% year to date to $356.83, even after the company beat second-quarter estimates for the fifth straight quarter with revenue of $2.89 billion and non-GAAP earnings per share of $2.80. Management cut full-year da Vinci procedure growth guidance to 13.5% to 15.5% from 18% in 2025, citing softer U.S. procedure growth, GLP-1-related bariatric case declines, and China tender softness, which sent shares down 11% the day after earnings. Bernstein, the most bullish analyst, maintains an Outperform rating with a $685 price target, implying nearly 92% upside, while the average Wall Street target is $484.40. The company repurchased $379 million of stock in the second quarter at an average price of $439, above current levels, and holds $8.6 billion in cash. Peer medtech stocks Medtronic and Stryker are down only 11% and 4% year to date, respectively, making Intuitive Surgical's decline a single-name reset with the widest analyst-implied upside in the group.
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
Abbott Laboratories is leaning into three of healthcare's most durable innovation themes: continuous glucose monitoring, oncology diagnostics and advanced cardiovascular treatment. Continuous glucose monitoring sales exceeded $2 billion in the second quarter of 2026 and grew 9.5% on a comparable basis, supported by the scale and adoption of FreeStyle Libre. Cancer Diagnostics sales totaled $919 million in the second quarter and grew 13.3% on a comparable basis, while Electrophysiology grew 13.4% on a comparable basis. The company also secured CE Mark for Libre Duo, a dual glucose-ketone wearable sensor, and expects Volt PFA, TactiFlex Duo, Amulet 360 and coronary intravascular lithotripsy launches to broaden its cardiovascular opportunity over the next 12 months. Abbott currently carries a Zacks Rank #3 (Hold), along with a VGM Score of C, a Growth Score of C, and a Momentum Score of A.
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance
Implicity has received FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI algorithm that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity for true events. The software works as a manufacturer-agnostic second layer on top of initial device filters, supporting monitors from Abbott, Biotronik, Boston Scientific, and Medtronic. Research published in EP Europace and Heart Rhythm demonstrated the algorithm's performance, and a 2026 multicenter study in JACC: Clinical Electrophysiology highlighted the ongoing burden of false-positive alerts across vendors, underscoring the need for such improvements. Implicity expects the analyzer to become commercially available to U.S. customers in the coming months.
Tonghua Dongbao's Insulin Aspart Injection Receives US FDA Marketing Approval
Tonghua Dongbao announced that its Insulin Aspart Injection, co-developed with Nanjing King-Friend Biochemical Pharmaceutical, has officially received marketing approval from the US Food and Drug Administration for improving glycemic control in adult and pediatric patients with diabetes.
Penumbra wins FDA clearance for THUNDERBOLT stroke thrombectomy system
Penumbra received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The clearance follows the THUNDER study, which reported strong safety and efficacy results for the device. A leading stroke center has already begun using THUNDERBOLT in clinical practice, expanding its real-world footprint. The system uses computer-assisted, modulated aspiration to automate part of the thrombectomy process, potentially offering hospitals more consistent clot removal and procedure times. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, and this clearance adds a new technology to its stroke portfolio at a time when hospitals seek more precise and efficient treatment tools.
Biotech IPOs Surge 55% as AI Listings Lose Momentum
Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.
Intuitive Surgical shares have fallen 38% year-to-date to a multi-year low not seen since early 2024, even after the company reported second-quarter revenue of $2.9 billion, a 19% year-over-year increase. The number of da Vinci procedures rose 15% and the installed base grew 12% to 11,710 systems, but the stock has been pressured by the expiration of Affordable Care Act enhanced premiums and a decline in bariatric cases linked to rising GLP-1 use. The sell-off has pushed the stock's forward earnings multiple down to 33 times, well below historical levels that often reached around 70, potentially making it a more attractive entry point for long-term investors.
Novo Nordisk Launches Once-Weekly Diabetes Combo Kyinsu in China via Fangzhou's AI Internet Hospital
Novo Nordisk and Fangzhou have launched Kyinsu, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, in China through Fangzhou's AI-driven Internet hospital. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform, targeting broader access for people living with diabetes. The partnership may influence how Novo Nordisk allocates capital between traditional channels and online care in large markets, while also testing a go-to-market model that ties the drug to a digital ecosystem for diagnosis, titration, adherence, and follow-up at scale. Analysts flag potential earnings pressure from competition and pricing, as well as operational and regulatory risks tied to the partner's AI and Internet-hospital infrastructure. Investors may watch how quickly Kyinsu uptake builds on Fangzhou's platform and whether Novo Nordisk extends similar digital-first launches to other products or markets.
J&J raises 2026 guidance after robust Q2, driven by Innovative Medicine
Johnson & Johnson raised its 2026 sales and earnings guidance after reporting second-quarter results that beat estimates, with earnings up 4.7% and sales up 6.6% from a year ago. The Innovative Medicine segment, which has recorded five consecutive quarters of sales above $15 billion, grew 6.2% organically in the first half of 2026 despite the loss of exclusivity for Stelara, driven by drugs like Darzalex, Erleada, and Tremfya, as well as newer products including Carvykti, Tecvayli, Talvey, Rybrevant, and Spravato. J&J believes 10 of its new products in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant plus Lazcluze, and Icotyde, with Icotyde alone seen as having $10 billion in sales potential. The MedTech segment slightly missed estimates with sales of $8.93 billion, as competitive pressures in electrophysiology and a 2% decline in Abiomed sales weighed on cardiovascular performance, though surgery, vision, and orthopedics all accelerated. J&J expects MedTech to improve in the second half of 2026 and remains confident in achieving around $100 billion in total revenues for the year, with a line of sight to double-digit growth by the end of the decade.
APP sees bright second half of 2026, booking backlog continuously, new models to provide support
APP signals a bright second half of 2026, accelerating revenue recognition from its backlog continuously, while benefiting from new car models gradually entering production lines in the third and fourth quarters. The company is also pushing forward with 3D metal printing to penetrate the personalized medical device market, partnering with Lerdsin Hospital to develop high-precision titanium parts. Chief Operating Officer Krikkrit Jearakamolchuen revealed that in the second quarter, the company was able to accelerate delivery of its order book well, although compared to the same period last year, there may be a difference due to the high revenue base from the previous year's low-volume production work for a subsidiary on a large-scale project. For the automotive business, APP remains strong in producing interior parts, especially plastic components such as seating systems and front consoles, supporting both internal combustion engine and electric vehicles. The company positions itself as a Tier 2 parts manufacturer, acting as a behind-the-scenes supporter for all Tier 1 manufacturers, reducing the risk of relying on a single customer and opening opportunities to supply parts to every car brand. In the medical business, the company is advancing 3D metal printing technology in collaboration with Lerdsin Hospital, a center for orthopedics, aiming to produce implantable devices from titanium metal, such as cranial plates and personalized medical devices requiring high precision. Additionally, the company continues to use a cross-product selling strategy to increase sales value from its existing customer base, while studying expansion into the defense industry and industrial automation systems, which are currently under discussion with partners and in the project development pipeline.
CareDx Soars on Medicare Coverage, AtaiBeckley Acquired by Eli Lilly, Abbott Lifts Outlook
Biotech stocks surged Thursday, led by CareDx which soared over 35% after Medicare finalized a policy confirming coverage for its transplant surveillance portfolio, including AlloSure Kidney and AlloMap Heart, effective August 30, 2026. AtaiBeckley jumped more than 33% on news it will be acquired by Eli Lilly in a deal valued at up to $3.8 billion, comprising $2.8 billion in upfront cash and up to $1.0 billion in contingent value rights tied to milestones for its depression treatments BPL-003 and VLS-01. Abbott Laboratories gained over 10% after reporting second-quarter net sales of $12.6 billion, a 13% increase, and raising its full-year adjusted earnings per share outlook to a range of $5.45 to $5.60. Apollomics added another 21%, bringing its weekly gain to more than 60%, as its lead candidate Vebreltinib advances in a Phase 2 trial for clear cell sarcoma and the company regained Nasdaq compliance. Virax Biolabs rose 13% after its CEO highlighted a narrowed net loss of $5.0 million, a $3.3 million capital raise, and a supply agreement with Fosun Diagnostics, while Entera Bio climbed over 12% ahead of a planned Phase 3 trial for its oral osteoporosis tablet EB613.
Abbott Laboratories Raises Full-Year Profit Forecast After Strong Second Quarter
Abbott Laboratories raised its full-year profit forecast on Thursday, driven by rising demand for medical devices and diagnostic tests. Second-quarter sales rose 13% to $12.6 billion, boosted by the $21 billion acquisition of cancer screening leader Exact Sciences in March. Worldwide diagnostics sales surged 42.3% to $3.1 billion, while medical device revenue grew 9% to $5.9 billion. Adjusted earnings per share came in at $1.31, beating Wall Street estimates of $1.28. Management now expects full-year adjusted earnings per share between $5.45 and $5.60, up from a prior range of $5.38 to $5.58, and comparable sales growth of 6.5% to 7.5% in 2026.
J&J Q2 profit beats estimates, raises full-year outlook on strong pharmaceuticals
US pharmaceutical giant Johnson & Johnson reported second-quarter adjusted earnings per share of $2.90, beating the average analyst estimate of $2.85. The pharmaceuticals division performed well, driving total revenue up about 7% year-on-year to $25.31 billion, above the expected $25.05 billion. Pharmaceutical sales came in at $16.38 billion, exceeding the forecast of $16.1 billion, with psoriasis treatment Tremfya surging 72.5% to $2 billion and blood cancer drug Darzalex also strong. Meanwhile, the medical devices unit posted revenue of $8.93 billion, missing the $8.97 billion estimate, as domestic demand for the Impella heart pump swung from a 14% gain in the prior quarter to a 2% decline. The company raised the midpoint of its full-year revenue outlook to $101.1 billion from $100.8 billion, and lifted the midpoint of its adjusted earnings per share forecast to $11.68 from $11.55.
Glucotrack Receives US Patent Allowance for Implantable Continuous Glucose Monitor
Glucotrack announced that the US Patent and Trademark Office issued a Notice of Allowance for a patent application covering its continuous blood glucose monitoring platform. The allowed patent expands intellectual property protection for the fully implantable system and includes electrode configurations, lead-based sensing structures, and associated implantation methods. This adds to three CBGM patents already issued in 2025. President and CEO Paul V. Goode stated that building intellectual property is fundamental to the company's strategy as it advances the system through clinical testing toward commercialization.
Eli Lilly Stock Could Reach $1,400 by End of 2026 on Expanded Drug Access
Eli Lilly's stock could climb to $1,400 by the end of 2026, driven by expanded access to its obesity treatments. The FDA recently approved Foundayo, the first GLP-1 pill for weight management that can be taken without food or water restrictions, removing barriers like refrigeration and injections. Eli Lilly has committed $27 billion to four new U.S. manufacturing sites, with three focused on small-molecule production for pills like Foundayo, and began shipping the drug through its LillyDirect platform with self-pay pricing starting near $149 a month. The company also reached agreements to lower costs for Medicare beneficiaries, who can pay as little as $50 a month for Zepbound and Foundayo, while commercial savings cards bring costs near $25 a month. Shares traded near $1,213 in early July, and the prediction of a 15% gain to $1,400 by year-end 2026 is based on the pill format, increased production capacity, and pricing deals that widen the patient base.
Novo Nordisk teams up with Vivani to test a semaglutide implant
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani's NanoPortal platform for chronic weight management. Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treatment. An implant based on Vivani's NanoPortal technology could, if successful, support long-term dosing from a single procedure, which may appeal to patients who struggle with adherence or do not want frequent injections. The collaboration adds another angle to Novo Nordisk's obesity care toolkit alongside existing Wegovy injections and tablets, and sits within a competitive field that includes Eli Lilly and newer GLP-1 developers.
Insulet launches Omnipod 5 and Omnipod Discover in Spain
Insulet Corporation has commercially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking the 20th country where Omnipod 5 is available and the 26th where the company sells its Omnipod products. Spain is home to more than 4.6 million adults with diabetes, including an estimated 189,000 individuals with type 1 diabetes. Omnipod 5 is a tubeless system that automatically adjusts insulin every five minutes and is indicated for people aged two years and older with type 1 diabetes, compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 sensors. The web-based Omnipod Discover platform provides retrospective data analytics and reporting to simplify diabetes insights for users, caregivers, and healthcare professionals. Insulet continues to work with Spanish health authorities to facilitate progressive and equitable access to these technologies.